News > Bharat Biotech completes clinical trials of India`s first intranasal Covid vaccine
Bharat Biotech completes clinical trials of India`s first intranasal Covid vaccine
Dais Newsfeed | 15/08/2022 09:12 PM | Click to read full article
India’s leading vaccine manufacturer Bharat Biotech International Limited (BBIL) on Monday said that it completed its Phase 3 clinical trials for its Covid-19 intranasal vaccine (BBV154), which has “proven to be safe, well-tolerated, and immunogenic in subjects.”
The vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery.